Products containing peony bark extract and applications thereof

Abstract

The present invention relates to a product containing peony bark extract and its application. The product of the present invention comprises the following components by weight: 40-60 parts of peony bark extract, 10-15 parts of locust leaves, 3-5 parts of osmanthus powder, 1-3 parts of filler, 0.5-4 parts of chitosan, and 1-3 parts of antioxidant; the peony bark extract and the locust leaves have significant synergistic effects of lowering blood pressure and blood lipids; and the addition of osmanthus powder in the process of preparing the peony bark extract can eliminate the slightly spicy taste of the peony bark and improve the taste of the product; and the addition of osmanthus powder also plays an antioxidant effect to a certain extent, which is beneficial to the stability of the product; the product of the present invention has a certain degree of sleep improvement effect while lowering blood pressure and blood lipids.

Description

Technical Field

[0001] The invention relates to a blood pressure lowering and blood lipid lowering auxiliary product containing peony bark extract, and particularly relates to an application and a specific preparation method thereof. Background Art

[0002] Peony is a plant of the Ranunculaceae family and the genus Paeonia, which has high ornamental, edible and medicinal value. The root of peony is processed into "Danpi", which is a precious Chinese herbal medicine. It is slightly cold in nature, spicy in taste, non-toxic, and enters the heart, liver, and kidney meridians. It has the functions of dispersing blood stasis, clearing blood, harmonizing blood, relieving pain, and dredge menstruation. Long-term consumption can benefit the body and prolong life, nourish blood and harmonize the liver, dissipate depression and remove blood stasis. It is suitable for facial chloasma and skin aging. Drinking it regularly can activate qi and blood, make the face ruddy, improve menstrual disorders, dysmenorrhea, and stop sweating and night sweats. Chemical analysis shows that peony petals and pollen contain a variety of substances that are beneficial to the human body. Eating them can cure diseases, and can increase nutrition and strengthen the body if there is no disease, such as peony cake. Peony seed oil contains 18 essential amino acids and a large number of trace elements that are beneficial to the human body. The total unsaturated fatty acid content is more than 92%, including 21.5% oleic acid, 28.5% linoleic acid, and 42.4% α-linolenic acid. It also contains rare biologically active ingredients such as vitamin E, vitamin F, squalene, phytosterols, etc. Many indicators exceed olive oil, making it a high-quality vegetable edible oil.

[0003] Peony stamens contain up to 120 mg / kg of rare vitamin B3, the highest content among all plant foods. Peony stamen tea, petal tea and peony leaf tea have been developed and marketed, and the market is in short supply.

[0004] In summary, each part of peony has unique efficacy value; among them, due to its texture and other factors, the utilization rate of peony bark is relatively lower than that of other parts of peony; although each part of peony has good health care effect, its efficacy is limited after all; in order to better utilize the efficacy of peony active ingredients and further explore the application value of peony, the present invention takes a new approach to explore whether peony bark has better coordination effect when combined with other plant raw materials, or whether it will produce new other effects. Summary of the invention

[0005] In view of this, the present invention provides a product containing peony bark extract for assisting in lowering blood pressure and blood lipids, and its preparation method and application. The peony bark extract with a pungent taste is prepared by a specific preparation method, and after being mixed with other plant raw materials, it can also have the coordinated auxiliary blood pressure and blood lipid lowering effects, and further has the effect of improving sleep.

[0006] The specific technical solutions of the present invention are as follows:

[0007] The auxiliary blood pressure lowering and blood lipid lowering product containing peony bark extract provided by the present invention comprises the following components in parts by weight: 40-60 parts of peony bark extract, 10-15 parts of locust tree leaves, 3-5 parts of osmanthus powder, 1-3 parts of filler, 0.5-4 parts of chitosan and 1-3 parts of antioxidant.

[0008] Preferably, the auxiliary blood pressure and blood lipid lowering product containing peony bark extract includes the following components in parts by weight: 40-55 parts of peony bark extract, 10-15 parts of locust tree leaves, 3-5 parts of osmanthus powder, 1-2 parts of filler, 1-4 parts of chitosan, and 1-3 parts of antioxidant.

[0009] Preferably, the auxiliary blood pressure and blood lipid lowering product containing peony bark extract includes the following components in parts by weight: 40-53 parts of peony bark extract, 10-14 parts of locust tree leaves, 3-5 parts of osmanthus powder, 1-2 parts of filler, 1-4 parts of chitosan, and 1-3 parts of antioxidant.

[0010] Preferably, the auxiliary blood pressure and blood lipid lowering product containing peony bark extract includes the following components in parts by weight: 41-53 parts of peony bark extract, 10-14 parts of locust tree leaves, 4 parts of osmanthus powder, 1-2 parts of filler, 1-4 parts of chitosan, and 1-2 parts of antioxidant.

[0011] Preferably, the auxiliary blood pressure and blood lipid lowering product containing peony bark extract includes the following components in weight parts: 41-53 parts of peony bark extract, 10-13 parts of locust tree leaves, 4 parts of osmanthus powder, 1-2 parts of filler, 2-4 parts of chitosan, and 2 parts of antioxidant.

[0012] Preferably, the auxiliary blood pressure and blood lipid lowering product containing peony bark extract includes the following components by weight: 42-53 peony bark extract, 10-13 locust tree leaves, 4 osmanthus powder, 1-2 fillers, 2-4 chitosans, and 2 antioxidants.

[0013] Preferably, the filler is any one of guar gum, corn starch and resistant dextrin.

[0014] Preferably, the antioxidant is any one of tea polyphenols, vitamin C, and butylated hydroxyanisole.

[0015] The Paeonia suffruticosa root extract is specifically prepared by the following method:

[0016] (1) Wash and crush the peony bark into 30-50 mesh, add 30-50 parts by weight of water, and boil for 20-40 minutes to obtain material A;

[0017] (2) adding trypsin and pectinase to material A for enzymolysis, adding 0.5-1 part of osmanthus powder during the enzymolysis process, and inactivating the enzyme at 90-95° C. for 5 min to obtain an enzymolysis material;

[0018] Enzymatic hydrolysis conditions: trypsin: pectinase = 3-5: 1-2, the total amount of enzyme added is 20-50% of the weight of material A; enzymatic hydrolysis temperature 35-45°C, enzymatic hydrolysis time 15-35min;

[0019] (3) subjecting the enzymatically hydrolyzed material to reflux alcohol extraction to obtain an alcohol-extracted concentrate;

[0020] (4) eluting the obtained alcohol-extracted concentrate with water in a macroporous resin column to obtain an eluate;

[0021] (5) The obtained eluate is concentrated to obtain a Paeonia suffruticosa root extract.

[0022] The osmanthus powder is specifically prepared by the following method:

[0023] (1) Take fresh whole osmanthus flowers, wash them and air-dry them for 3-6 hours;

[0024] (2) stir-frying the mixture at 120-150° C. until the water content reaches 40-60%, and then stir-frying the mixture again until the water content reaches 10-20% after natural cooling; and cooling the mixture in batches;

[0025] (3) The cooled osmanthus flowers are rolled and then ultrasonically crushed for 60-150 seconds at 30-100 kHz to obtain osmanthus powder.

[0026] The invention adopts the stir-frying method to prepare the osmanthus powder because, through tests and comparisons, the osmanthus fragrance of the osmanthus powder prepared by stir-frying is far superior to the fragrance of the osmanthus powder obtained by ordinary heating, drying and crushing.

[0027] The preparation method of the product is as follows:

[0028] (1) taking a peony bark extract, adding a locust leaf, stirring thoroughly, and then ultrafine grinding at room temperature for 20-60 minutes to obtain a mixed material A;

[0029] (2) adding osmanthus powder to material A, mixing well and then sequentially adding filler, chitosan and antioxidant to obtain mixed material B;

[0030] (3) homogenizing the obtained mixed material B at 30-40 MPa for 10-30 min;

[0031] (4) Sterilization and obtaining the finished product.

[0032] The product prepared by the present invention can be used in preparing products with both auxiliary blood pressure lowering and blood lipid lowering effects.

[0033] Paeonia suffruticosa root bark is the dried root bark of the Ranunculaceae plant Paeonia suffruticosa. It is bitter and pungent, and enters the heart, liver, and kidney meridians. It has the effects of clearing heat and cooling blood, promoting blood circulation and removing blood stasis, and relieving deficiency fever.

[0034] Sophora japonica leaves can clear the liver and purge fire; cool the blood and detoxify; dry dampness and kill insects; "Compendium of Materia Medica" says: "The newly born tender buds of Sophora japonica can be fried and washed in water and eaten, or they can be drunk instead of tea.

[0035] Osmanthus powder has the effects of warming the stomach and calming the liver, benefiting the kidneys and dispelling cold, removing odor and detoxifying, moistening the intestines and relieving constipation, and relieving flatulence; it can also whiten the skin, eliminate toxins in the body, make people feel relaxed and at ease.

[0036] The invention adds osmanthus to increase the fragrance of osmanthus. It is also found in the experiment that it can effectively overcome the spicy taste and astringent taste of peony bark itself, improve the taste of the product, and also has the effect of auxiliary anti-oxidation.

[0037] The beneficial effects of the present invention are:

[0038] 1. Peony bark extract combined with Sophora japonica leaves can coordinate and promote the effect of assisting in lowering blood pressure and blood lipids; this is an effect that cannot be achieved when peony bark extract is combined with other plant raw materials such as mulberry leaves or Eucommia ulmoides leaves; and after testing, it meets various safety indicators; this shows that when peony bark extract is combined with Sophora japonica leaves, it has the effect of synergistically improving the effect of assisting in lowering blood pressure and blood lipids. The specific blood lipid-lowering performance is: it can play a certain role in increasing high-density lipoprotein cholesterol and reducing low-density lipoprotein cholesterol, effectively reducing blood lipids, and achieving the beneficial effect that the test groups 2 and 3 in the test could not achieve;

[0039] 2. After taking the product prepared by the present invention, some of the subjects showed improvement in sleep and mental state, indicating that the product of the present invention may improve sleep and mental state to a certain extent, achieving an unexpected effect;

[0040] 3. In the preparation process of peony extract, the addition of osmanthus powder can overcome the spiciness and astringency of peony bark itself, which is an effect that cannot be achieved by adding other pollens. DETAILED DESCRIPTION

[0041] 1. Implementation

[0042] Example 1

[0043] The auxiliary blood pressure and blood lipid lowering product containing peony bark extract comprises the following components in parts by weight: 45 parts of peony bark extract, 10 parts of locust tree leaves, 4 parts of osmanthus powder, 1 part of corn starch, 2 parts of chitosan and 2 parts of tea polyphenols.

[0044] The peony bark extract is prepared by the following method:

[0045] (1) Wash and crush the peony bark into 30 mesh, add 50 parts by weight of water, and boil for 30 minutes to obtain material A;

[0046] (2) adding trypsin and pectinase to material A for enzymolysis, adding 0.5 parts of osmanthus powder during the enzymolysis process, inactivating the enzyme at 90° C. for 5 min, and obtaining an enzymolysis material;

[0047] Enzymatic hydrolysis conditions: trypsin: pectinase = 5:2, the total amount of enzyme added is 20% of the weight of material A; enzymatic hydrolysis temperature 38°C, enzymatic hydrolysis time 20min;

[0048] (3) subjecting the enzymatically hydrolyzed material to reflux alcohol extraction to obtain an alcohol-extracted concentrate;

[0049] (4) eluting the obtained alcohol-extracted concentrate with water in a macroporous resin column to obtain an eluate;

[0050] (5) The obtained eluate is concentrated to obtain a Paeonia suffruticosa root extract.

[0051] The osmanthus powder is prepared by the following method:

[0052] (1) Take fresh whole osmanthus flowers, wash them and air-dry them for 4 hours;

[0053] (2) stir-frying the mixture at 150° C. until the water content reaches 50%, and then stir-frying the mixture again until the water content reaches 10% after natural cooling; and cooling the mixture in batches;

[0054] (3) The cooled osmanthus flowers are rolled and then ultrasonically crushed at 60 kHz for 120 seconds to obtain osmanthus powder.

[0055] The preparation method of the product is as follows:

[0056] (1) Take the peony bark extract, add the leaves of Sophora japonica, stir thoroughly, and then perform ultrafine grinding at room temperature for 20 minutes to obtain a mixed material A;

[0057] (2) adding osmanthus powder to material A, mixing well and then sequentially adding filler, chitosan and antioxidant to obtain mixed material B;

[0058] (3) homogenizing the obtained mixed material B at 40 MPa for 15 min;

[0059] (4) Sterilization and obtaining the finished product.

[0060] Example 2

[0061] The auxiliary blood pressure and blood lipid lowering product containing peony bark extract comprises the following components in parts by weight: 50 parts of peony bark extract, 12 parts of locust tree leaves, 3 parts of osmanthus powder, 1 part of corn starch, 2 parts of chitosan and 2 parts of vitamin C.

[0062] The peony bark extract is prepared by the following method:

[0063] (1) Wash and crush the peony bark into 30 meshes, add 50 parts by weight of water and boil for 30 minutes to obtain material A;

[0064] (2) adding trypsin and pectinase to material A for enzymolysis, adding 1 part of osmanthus powder during the enzymolysis process, and inactivating the enzyme at 90° C. for 5 min to obtain an enzymolysis material;

[0065] Enzymatic hydrolysis conditions: trypsin: pectinase = 3:2, the total amount of enzyme added is 20% of the weight of material A; enzymatic hydrolysis temperature 38°C, enzymatic hydrolysis time 20min;

[0066] (3) subjecting the enzymatically hydrolyzed material to reflux alcohol extraction to obtain an alcohol-extracted concentrate;

[0067] (4) eluting the obtained alcohol-extracted concentrate with water in a macroporous resin column to obtain an eluate;

[0068] (5) The obtained eluate is concentrated to obtain a Paeonia suffruticosa root extract.

[0069] The osmanthus powder is prepared by the following method:

[0070] (1) Take fresh whole osmanthus flowers, wash them and air-dry them for 4 hours;

[0071] (2) stir-frying the mixture at 150° C. until the water content reaches 50%, and then stir-frying the mixture again until the water content reaches 10% after natural cooling; and cooling the mixture in batches;

[0072] (3) The cooled osmanthus flowers are rolled and then ultrasonically crushed at 60 kHz for 120 seconds to obtain osmanthus powder.

[0073] The preparation method of the product is as follows:

[0074] (1) Take the peony bark extract, add the leaves of Sophora japonica, stir thoroughly, and then perform ultrafine grinding at room temperature for 20 minutes to obtain a mixed material A;

[0075] (2) adding osmanthus powder to material A, mixing well and then sequentially adding filler, chitosan and antioxidant to obtain mixed material B;

[0076] (3) homogenizing the obtained mixed material B at 40 MPa for 15 min;

[0077] (4) Sterilization and obtaining the finished product.

[0078] Example 3

[0079] The auxiliary blood pressure and blood lipid lowering product containing peony bark extract comprises the following components in parts by weight: 48 parts of peony bark extract, 10 parts of locust tree leaves, 3 parts of osmanthus powder, 1 part of resistant dextrin, 2 parts of chitosan and 2 parts of tea polyphenols.

[0080] The peony bark extract is prepared by the following method:

[0081] (1) Wash and crush the peony bark into 30 meshes, add 50 parts by weight of water and boil for 30 minutes to obtain material A;

[0082] (2) adding trypsin and pectinase to material A for enzymolysis, adding 0.5 parts of osmanthus powder during the enzymolysis process, and inactivating the enzyme at 90° C. for 5 min to obtain an enzymolysis material;

[0083] Enzymatic hydrolysis conditions: trypsin: pectinase = 4:2, the total amount of enzyme added is 20% of the weight of material A; enzymatic hydrolysis temperature 38°C, enzymatic hydrolysis time 20min;

[0084] (3) subjecting the enzymatically hydrolyzed material to reflux alcohol extraction to obtain an alcohol-extracted concentrate;

[0085] (4) eluting the obtained alcohol-extracted concentrate with water in a macroporous resin column to obtain an eluate;

[0086] (5) The obtained eluate is concentrated to obtain a Paeonia suffruticosa root extract.

[0087] The osmanthus powder is prepared by the following method:

[0088] (1) Take fresh whole osmanthus flowers, wash them and air-dry them for 4 hours;

[0089] (2) stir-frying the mixture at 150° C. until the water content reaches 50%, and then stir-frying the mixture again until the water content reaches 10% after natural cooling; and cooling the mixture in batches;

[0090] (3) The cooled osmanthus flowers are rolled and then ultrasonically crushed at 60 kHz for 120 seconds to obtain osmanthus powder.

[0091] The preparation method of the product is as follows:

[0092] (1) Take the peony bark extract, add the leaves of Sophora japonica, stir thoroughly, and then perform ultrafine grinding at room temperature for 20 minutes to obtain a mixed material A;

[0093] (2) adding osmanthus powder to material A, mixing well and then sequentially adding filler, chitosan and antioxidant to obtain mixed material B;

[0094] (3) homogenizing the obtained mixed material B at 40 MPa for 15 min;

[0095] (4) Sterilization and obtaining the finished product.

[0096] In Example 4, "osmanthus powder" is replaced by "sophora flower powder". The preparation method of sophora flower powder is the same as that of osmanthus powder, and the rest is the same as that of Example 1.

[0097] In Example 5, "sophora japonica leaves" are replaced by "mulberry leaves", and the rest is the same as in Example 1.

[0098] In Example 6, "Sophora japonica leaves" are replaced by "Eucommia ulmoides leaves", and the rest is the same as in Example 1.

[0099] 2. Index detection

[0100] 1. Safety indicators

[0101] 1.1 General condition (including mental state, sleep, diet, bowel movements, blood pressure, etc.)

[0102] 1.2 Routine examination of blood, urine and stool

[0103] 1.3 Liver and kidney function tests

[0104] 1.4 Chest X-ray, electrocardiogram, and abdominal B-ultrasound examination (only performed before the start of the trial)

[0105] 2 Efficacy indicators

[0106] Serum total cholesterol (TC) level and reduction percentage, triglyceride (TG) level and reduction percentage, high-density lipoprotein cholesterol (HDL-C) level and increase, low-density lipoprotein cholesterol (LDL-C) level.

[0107] Blood pressure and heart rate measurement: Blood pressure and heart rate are measured once a week at a fixed time. The subjects rest for 15-20 minutes before measurement.

[0108] 3. Efficacy criteria

[0109] Effective: TC decreased by >10%; TG decreased by >15%; HDL-C increased by >0.104mmol / L;

[0110] Diastolic blood pressure drops by ≥10 mmHg or drops to normal (<80 mmHg);

[0111] Systolic blood pressure drops by ≥20 mmHg or drops to normal (<120 mmHg);

[0112] Invalid: Those who do not meet the validity criteria.

[0113] The serum total cholesterol effective rate, triglyceride effective rate, high-density lipoprotein cholesterol effective rate and total effective rate were observed.

[0114] Blood pressure was scored before and after the trial according to the severity of symptoms (3 points for severe symptoms, 2 points for moderate symptoms, and 1 point for mild symptoms), and the improvement rate was calculated (an improvement of 1 point or more was considered effective).

[0115] 3. Results

[0116] 1. Balance comparison results

[0117] 162 subjects were included, 54 in trial group 1, 54 in trial group 2, and 54 in trial group 3. Excluding 3 subjects dropped out of each trial group, there were 153 subjects, 51 in each trial group. As shown in Table 1, there was no significant difference in blood lipid level, blood pressure, age, and gender among the trial groups before the trial (P>0.05), which was balanced and comparable.

[0118] Table 1 Comparison of blood lipid, age and gender balance before tasting

[0119]

[0120] 2. Safety index analysis results

[0121] 2.1 Comparison of general conditions of each test group

[0122] The test subjects were asked about their mental state, sleep, diet, and bowel movements, and their scores were divided into good, average, and poor categories. Their blood pressure and heart rate were also measured. As shown in Table 2, most of the test subjects were in good general condition. When comparing themselves before and after the test, all indicators showed no adverse changes, indicating that the test had no adverse effects on the subjects' general condition.

[0123] Test group 1: took the product of Example 1;

[0124] Test group 2: took the product of Example 5;

[0125] Test group 3: took the product of Example 6.

[0126] Table 2 Comparison of general conditions before and after the tasting

[0127]

[0128] It can be seen from the above table that after taking the product of Example 1, the sleep condition of some people improved from fair to good, while the subjects who took the product of Example 6 did not show any improvement in sleep or mental state; this indicates that the product prepared by the present invention may have the effect of improving sleep and mental state to a certain extent.

[0129] Table 3 Changes in blood, urine, stool routine and blood biochemistry before and after the trial

[0130]

[0131] All the above indicators were basically within the normal range before and after the test.

[0132] 2.2. Results of efficacy index analysis

[0133] 2.2.1 Effects of the test substances on serum total cholesterol

[0134] Table 4 Effects of the test substances on serum total cholesterol ( mmol / L)

[0135]

[0136] Note: **P<0.01 for self-comparison, ##P<0.01 for inter-group comparison

[0137] As shown in Table 4, the difference in serum total cholesterol content before and after the trial in the first trial group was significant (P<0.01), and the level after the trial was lower than that before the trial; there was no significant difference in serum total cholesterol content before and after the trial in the second and third trial groups (P>0.05);

[0138] 2.2.2 Effects of the test substances on serum triglycerides

[0139] Table 5 Effects of the test substances on serum triglycerides ( mmol / L)

[0140]

[0141] Note: **P<0.01 for self-comparison, ##P<0.01 for inter-group comparison

[0142] As can be seen from Table 5, there was a significant difference in the serum triglyceride content of trial group 1 before and after the trial (P<0.01), and the level after the trial was lower than that before the trial; there was no significant difference in the serum triglyceride content of trial group 2 and trial group 3 before and after the trial (P>0.05); there was no significant difference in the serum triglyceride content between trial group 1 and trial groups 2 and 3 before the trial (P>0.05); after the trial, the serum triglyceride content of trial group 1 was significantly lower than that of trial groups 2 and 3 (P<0.01), and the decrease rate was significantly different.

[0143] 2.2.3 Effects of the test substances on serum low-density lipoprotein cholesterol

[0144] Table 6 Effects of the test substances on serum low-density lipoprotein cholesterol ( mmol / L)

[0145]

[0146] Note: **P<0.01 for self-comparison, ##P<0.01 for inter-group comparison

[0147] As can be seen from Table 6, there was a significant difference in the serum low-density lipoprotein cholesterol content between the trial group 1 before and after the trial (P<0.01), and the serum low-density lipoprotein cholesterol content after the trial was lower than that before the trial; there was no significant difference in the serum low-density lipoprotein cholesterol content between the trial group 2 and the trial group 3 before and after the trial (P>0.05); there was no significant difference in the serum low-density lipoprotein cholesterol content between the trial group 1 and the trial groups 2 and 3 before the trial (P>0.05); after the trial, the serum low-density lipoprotein cholesterol content of the trial group 1 was significantly lower than that of the trial groups 2 and 3 (P<0.01).

[0148] 2.2.4 Effects of the test substances on serum high-density lipoprotein cholesterol

[0149] Table 7 Effects of the test substances on serum high-density lipoprotein cholesterol ( mmol / L)

[0150]

[0151] As can be seen from Table 7, there was no significant difference in the serum high-density lipoprotein cholesterol content between trial group 1 and trial groups 2 and 3 before and after the trial (P>0.05); there was no significant difference in the serum high-density lipoprotein cholesterol content between trial group 1 and trial groups 2 and 3 before and after the trial (P>0.05).

[0152] Table 8 Comparison of effective rates

[0153]

[0154] Note: Total effectiveness means that the total cholesterol reduction rate is greater than 10%, and the triglyceride reduction rate is greater than 15%.

[0155] As shown in Table 8, the total effective rate of trial group 1 was 21.6%, and the total effective rate of trial group 3 was 0. There was a significant difference in the total effective rates between the two groups (P<0.01).

[0156] In summary, the product of the present invention can increase high-density lipoprotein cholesterol and reduce low-density lipoprotein cholesterol to a certain extent after taking, effectively lowering blood lipids, achieving the beneficial effects that trial groups 2 and 3 could not achieve.

[0157] 2.2.5 Comparison of blood pressure and heart rate before and after the trial

[0158] Table 9 Comparison of blood pressure and heart rate before and after the tasting

[0159]

[0160] Note: Self-comparison *P<0.05**P<0.01 Inter-group comparison #P<0.05##P<0.01

[0161] As can be seen from Table 9, the systolic and diastolic blood pressures of the trial group 1 decreased before and after the trial, and the difference was significant (P < 0.01). The systolic blood pressure of the trial group 1 decreased by an average of 2.83 mmHg, and the diastolic blood pressure decreased by an average of 2.19 mmHg. There was no significant difference in the systolic and diastolic blood pressures of the trial group 3 before and after the trial. After the trial, the systolic and diastolic blood pressures of the trial group were lower than those of the trial group 3, and the difference was significant (P < 0.05).

[0162] 2.2.6 Symptom score

[0163] Table 10 Improvement of main symptoms

[0164]

[0165] Note: The data in “()” are for test group 3, and the data outside “()” are for test group 1;

[0166] Table 11 Changes in symptom scores before and after the trial meal

[0167]

[0168] Self-comparison **P<0.01, inter-group comparison ##P<0.01

[0169] As can be seen from the above table, the symptom scores of trial group 1 before and after the trial were reduced and the difference was significant (P<0.01), while there was no significant difference in trial group 3 before and after the trial (P>0.05); after the trial, the symptom scores of trial group 1 were significantly reduced compared with those of trial group 3 (P<0.01).

[0170] 2.2.7 Dropout rate of subjects

[0171] There were 54 subjects in each trial group. Three subjects in each trial group failed to be re-examined on time at the prescribed time, meeting the exclusion criteria. There were 51 valid subjects in trial group (1) and 51 in trial group (3). The dropout rates of trial group 1 and trial group 3 were 5.6% and 5.6%, respectively.

[0172] Adverse reaction observation: No allergic or other adverse reactions were observed.

[0173] Table 12 Allergic and other adverse reactions during the trial period

[0174]

[0175] Based on the above evaluation results, when the peony bark extract is combined with the leaves of Sophora japonica, it can play a good role in assisting the lowering of blood pressure and blood lipids while ensuring safety; when the peony bark extract is combined with mulberry leaves or Eucommia ulmoides leaves, the effect is very small or even has no effect of assisting the lowering of blood pressure and blood lipids. This shows that when the peony bark extract is combined with the leaves of Sophora japonica, it has the effect of synergistically improving the effect of assisting the lowering of blood pressure and blood lipids. At the same time, the data in Table 2 also show that the product prepared by the present invention may play a role in improving sleep and mental state to a certain extent, achieving unexpected results.

[0176] 3 Sensory evaluation

[0177] The present invention also conducted a flavor evaluation on the products of each experimental group, as follows:

[0178] Test groups AC: products of Examples 1-3, respectively;

[0179] Tasting group D: product of Example 4.

[0180] Table 13 Sensory evaluation of different test substances

[0181]

[0182] Note: The higher the score, the better the sensory flavor.

[0183] It can be seen from the above table that in the preparation process of peony extract, the addition of osmanthus powder can overcome the spiciness and astringency of peony bark itself, which is an effect that cannot be achieved by adding other pollens.

[0184] In addition, during the storage process, it was found that the flavor of the products of Examples 1-3 deteriorated about 30-45 days later than that of Example 4, which may be due to the auxiliary antioxidant effect of the osmanthus powder added in the present invention.

Claims

1. A product containing a peony bark extract, characterized in that: The invention is prepared from the following components by weight: 45 parts of peony bark extract, 10 parts of locust tree leaves, 4 parts of osmanthus powder, 1 part of corn starch, 2 parts of chitosan and 2 parts of tea polyphenols; The osmanthus powder is prepared by the following method: (1) Take fresh whole osmanthus flowers, wash them and dry them naturally for 4 hours; (2) Stir-fry at 150°C until the water content reaches 50%, and then stir-fry again until the water content reaches 10% after natural cooling; and then cool the mixture in batches; (3) rolling the cooled osmanthus flowers and subjecting them to ultrasonic grinding for 120 seconds at 60 kHz to obtain osmanthus powder; The peony bark extract is prepared by the following method: (1) Wash and crush the peony bark into 30 mesh, add 50 parts by weight of water, and boil for 30 minutes to obtain material A; (2) Add trypsin and pectinase to material A for enzymolysis, add 0.5 parts of osmanthus powder during the enzymolysis process, inactivate the enzyme at 90°C for 5 minutes, and obtain an enzymolysis material; Enzymatic hydrolysis conditions: trypsin: pectinase = 5:2, the total amount of enzyme added is 20% of the weight of material A; enzymatic hydrolysis temperature 38°C, enzymatic hydrolysis time 20min; (3) subjecting the enzymatically hydrolyzed material to reflux alcohol extraction to obtain an alcohol extract; (4) eluting the obtained alcohol extract with water in a macroporous resin column to obtain an eluate; (5) Concentrating the obtained eluate to obtain the Paeonia suffruticosa root extract.

2. The product according to claim 1, characterized in that The preparation method of the product is as follows: (1) Take the peony bark extract, add the leaves of Sophora japonica, stir thoroughly, and then perform ultrafine grinding at room temperature for 20 minutes to obtain a mixed material A; (2) adding osmanthus powder to the mixed material A, mixing evenly, and then sequentially adding corn starch, chitosan, and tea polyphenols to obtain a mixed material B; (3) homogenizing the obtained mixed material B at 40 MPa for 10-30 min; (4) Sterilize and obtain the finished product.

Images